RYE, N.Y., Aug. 29, 2011 /PRNewswire/ -- Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for reduction in hyperactivity in mice treated with amphetamines. The mouse model screening was performed by the contract research organization, Cerca Insights.
The data indicated that the amphetamine-injected C57BL/6 mice exhibited a dose dependent reduction in hyperactivity when administered CM-182. Administration of CM-182 to control mice demonstrated no sedating effects, suggesting that the reduction of hyperactivity in the amphetamine induced mice was not due to any sedating effect of the compound.
"Our findings in the C57BL/6 mouse model with amphetamine induced hyperactivity are consistent with findings of other psychotropic medications utilized to treat hyperactivity, but without the sedating effects," states James Szigethy R.Ph., Director of Curemark Research and Development. "This further reinforces our previous findings using CM-182 to reduce hyperactivity in the ckr (chakragati) mouse model of schizophrenia."
"We are excited by these findings," states Dr. Joan Fallon, CEO of Curemark. "Our results demonstrate that our novel compound indeed shows promise for the treatment of hyperactivity without sedation. Hyperactivity is generally treated with a multiplicity of drugs that cause major sedation, and thereby alter the quality of life of those taking the drugs."
Curemark said it intends to pursue further its investigative studies on CM-182.
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
|SOURCE Curemark, LLC|
Copyright©2010 PR Newswire.
All rights reserved